The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat‐Pirenne, A Habibi… - Vox …, 2015 - Wiley Online Library
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBC s). Immunized patients have a high …
被引用次数：60 相关文章

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox …, 2015 - inserm.hal.science
Background: Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat-Pirenne, A Habibi… - Vox …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox Sanguinis, 2015 - hal.science
Background: Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox …, 2014 - europepmc.org
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat‐Pirenne, A Habibi, A Mekontso‐Dessap… - Vox Sanguinis, 2015 - infona.pl
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBC s). Immunized patients have a high …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.

F Noizat‐Pirenne, A Habibi… - Vox …, 2015 - search.ebscohost.com
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …
[PDF] researchgate.net

[PDF][PDF] The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox …, 2015 - researchgate.net
Background Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox Sanguinis, 2015 - hal.science
Background: Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …

The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease

F Noizat-Pirenne, A Habibi, A Mekontso-Dessap… - Vox …, 2015 - inserm.hal.science
Background: Delayed haemolytic transfusion reaction (DHTR) is mainly caused by an
immune response to transfused red blood cells (RBCs). Immunized patients have a high risk …